Lipitor® (atorvastatin calcium) 80 mg was associated with a
significantly reduced risk of major cardiovascular events compared with
Lipitor 10 mg among patients with both coronary heart disease (CHD) and
chronic kidney disease (CKD) who were obese or had metabolic syndrome.
These data, from two sub-analyses of the Treating to New Targets (TNT)
trial that were designed and completed following the completion of TNT,
were presented today at the 59th Annual Scientific
Session of the American College of Cardiology (ACC) in Atlanta, Ga.
“Nearly 26 million Americans suffer from CKD, which is often associated
with co-morbidities – such as heart disease, metabolic syndrome or
obesity – that can increase risk for heart attack and stroke”
“Nearly 26 million Americans suffer from CKD, which is often associated
with co-morbidities – such as heart disease, metabolic syndrome or
obesity – that can increase risk for heart attack and stroke,” said Dr.
Prakash Deedwania, professor of Medicine, UCSF School of Medicine, San
Francisco, CA and Chief, Cardiology Section, VACCHCS/UCSF Program,
Fresno, CA. “The new data presented at ACC demonstrate that Lipitor 80
mg may help prevent cardiovascular events in these high-risk patients.”
According to the new analyses, for patients with both CHD and CKD, being
obese or having metabolic syndrome may further increase their risk for
cardiovascular events.